Semi Xilia MP 1mg/500mg/7.5mg Tablet SR
Marketer
Emcure Pharmaceuticals Ltd
Salt Composition
Glimepiride (1mg) + Metformin (500mg) + Pioglitazone (7.5mg)
Overview Semi Xilia MP 1mg/500mg/7.5mg Tablet SR
Xylo-Trio 1 mg/500 mg/7.5 mg Extended-Release Tablets combine ingredients to manage blood glucose. This medication, used alongside diet and exercise, improves glycemic control in adults with type 2 diabetes. It enhances insulin effectiveness, thus reducing blood sugar. Adhere strictly to your doctor's prescribed dosage and frequency for Xylo-Trio 1 mg/500 mg/7.5 mg Extended-Release Tablets. Take it with food to minimize digestive discomfort. If a dose is missed, take it promptly; however, if nearing the next dose, omit the missed one and resume your normal schedule. Never double the dose. An overdose can cause dangerously low blood sugar (hypoglycemia). Concomitant use with other diabetes medications, alcohol, or skipped meals may increase hypoglycemia risk. Regular blood glucose monitoring is crucial. Common side effects include nausea, diarrhea, abdominal pain, headache, bone fractures, and respiratory infections. Prior to commencing treatment, disclose any kidney, liver, or heart conditions to your physician. Pregnant or nursing women require medical consultation before use. Kidney function tests will be conducted before treatment initiation. Limit alcohol consumption as it may heighten the risk of adverse effects.
Uses of Semi Xilia MP 1mg/500mg/7.5mg Tablet SR
Managing Type 2 Diabetes
Major Benefits of Semi Xilia MP 1mg/500mg/7.5mg Tablet SR:
Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The Semi Xilia MP 1 mg/500 mg/7.5 mg sustained-release tablet should be administered with food.
Common Side effects of Semi Xilia MP 1mg/500mg/7.5mg Tablet SR:
- Hypoglycemia (low blood glucose level)
- Headache
- Nausea
- Diarrhea
- Dizziness
- Vomiting
- Anemia (low number of red blood cells)
- Weakness
- Sinus infection
How to use Semi Xilia MP 1mg/500mg/7.5mg Tablet SR:
Administer this medication precisely as directed by your physician, adhering to the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or breaking it. Consume Semi Xilia MP 1 mg/500 mg/7.5 mg Extended-Release Tablets with food.
How Semi Xilia MP 1mg/500mg/7.5mg Tablet SR works:
Semi Xilia MP 1 mg/500 mg/7.5 mg Extended-Release Tablets contain glimepiride, metformin, and pioglitazone, three antidiabetic agents with distinct actions. This triple combination improves blood glucose management when monotherapy or dual therapy proves insufficient. Glimepiride, a sulfonylurea, stimulates pancreatic insulin secretion to reduce blood glucose levels. Metformin, a biguanide, acts by decreasing hepatic glucose production, slowing intestinal glucose absorption, and enhancing insulin sensitivity. Pioglitazone, a thiazolidinedione, further amplifies insulin sensitivity.
SAFETY ADVICE
AlcoholUNSAFE
Combining Semi Xilia MP 1 mg/500 mg/7.5 mg SR tablets with alcohol is unsafe.
PregnancyCONSULT YOUR DOCTOR
The use of Semi Xilia MP 1 mg/500 mg/7.5 mg Tablet SR during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against possible risks prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Prolonged-release Semi Xilia MP tablets (1 mg/500 mg/7.5 mg) are likely unsafe for breastfeeding mothers. Available evidence from human studies indicates potential transfer to breast milk, posing a risk to the infant.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.
KidneyCAUTION
Exercise caution when administering Semi Xilia MP 1 mg/500 mg/7.5 mg Tablet SR to individuals with impaired kidney function; dosage modification may be necessary. Consult a physician for guidance. The use of Semi Xilia MP 1 mg/500 mg/7.5 mg Tablet SR is contraindicated in patients exhibiting severe kidney disease. Close monitoring of renal function is recommended throughout the course of treatment.
LiverCAUTION
Exercise caution when administering Semi Xilia MP 1 mg/500 mg/7.5 mg SR tablets to individuals with hepatic impairment. Dosage modification may be necessary. Physician consultation is advised. Semi Xilia MP 1 mg/500 mg/7.5 mg SR tablets are contraindicated in patients exhibiting severe liver dysfunction.
What if you forget to take Semi Xilia MP 1mg/500mg/7.5mg Tablet SR :
Should you forget a dose of Semi Xilia MP 1 mg/500 mg/7.5 mg Extended-Release Tablet, ingest it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Semi Xilia MP 1mg/500mg/7.5mg Tablet SR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Management |
3,018 People bought this recently